Resistance of Cancer Cells to CTL-Mediated Immunotherapy
Editors: Bonavida, Benjamin, Chouaib, Salem (Eds.)
Free Preview- Explores the inhibition of CTL-cytotoxic function by tumor-derived T-regulatory cells, along with the inhibition of cytotoxic function by tumor induction of hypoxia
- Discusses the overexpression of transcription factors that regulate resistance
- Appeals to cancer researchers, biologists and immunologists
Buy this book
- About this book
-
This comprehensive volume explores the latest research on the mechanisms of resistance in cancer cells to CTL-mediated immunotherapy. Chapter topics discuss cell-mediated immunity as the result of cytotoxic T-lymphocytes (CTL) directed specifically against cancer cells. In addition, the volume reviews how CTL mediate the cytotoxic activity, in large part, by the indication of apoptosis; hence, tumor cells develop anti-apoptotic mechanisms and thereby, resist CTL-induced apoptosis. In order for CTL-mediated antitumor immunotherapy to be effective, it is essential that agents directed against the resistant tumor cells sensitized cancer cells for CTL-mediated apoptosis. Examples of such agents discussed in the volume include are HDAC inhibitors, proteasome inhibitors, Bcl-2 family inhibitors, PARP, antibodies, and more.
- About the authors
-
Benjamin Bonavida, Ph.D., is Professor, UCLA David Geffen School of Medicine for the Department of Microbiology, Immunology & Molecular Genetics. He is also Member, Department of Defense Congressionally Directed Medical Research Program, Member, National Cancer Institute SPORE Program, Member, International Scientific Advisory Board of the Israel Cancer Research Foundation, among other accomplishments. He is currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. He has published over 450 papers and reviews, has received more than 7,980 citations, and has edited four Springer volumes.
Salem Chouaib, Ph.D., is Head, Cancer Immunology Division at Institut Gustave Roussy. His research focuses on augmenting cytotoxic T cell immunity and studies how tumors evade the immune system. Dr. Chouaib has published more than 239 scientific papers and reviews, and has received more than 5,490 citations.
- Table of contents (15 chapters)
-
-
Resistance of Cancer Stem Cells to Cell-Mediated Immune Responses
Pages 3-29
-
Role of Co-inhibitory Molecules in Tumor Escape from CTL Attack
Pages 31-58
-
Role of the Non-classical HLA Class I Antigens for Immune Escape
Pages 59-72
-
Integrins: Friends or Foes of Antitumor Cytotoxic T Lymphocyte Response
Pages 73-89
-
Cytotoxic T Lymphocytes and Their Granzymes: An Overview
Pages 91-112
-
Table of contents (15 chapters)
Recommended for you
Bibliographic Information
- Bibliographic Information
-
- Book Title
- Resistance of Cancer Cells to CTL-Mediated Immunotherapy
- Editors
-
- Benjamin Bonavida
- Salem Chouaib
- Series Title
- Resistance to Targeted Anti-Cancer Therapeutics
- Series Volume
- 7
- Copyright
- 2015
- Publisher
- Springer International Publishing
- Copyright Holder
- Springer International Publishing Switzerland
- eBook ISBN
- 978-3-319-17807-3
- DOI
- 10.1007/978-3-319-17807-3
- Hardcover ISBN
- 978-3-319-17806-6
- Softcover ISBN
- 978-3-319-38067-4
- Series ISSN
- 2196-5501
- Edition Number
- 1
- Number of Pages
- XIX, 353
- Number of Illustrations
- 11 b/w illustrations, 27 illustrations in colour
- Topics
